Related references
Note: Only part of the references are listed.Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study
Clive Ballard et al.
LANCET NEUROLOGY (2018)
Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial
Clive Ballard et al.
PLOS MEDICINE (2018)
Epidemiology of Pain in People With Dementia Living in Care Homes: Longitudinal Course, Prevalence, and Treatment Implications
Anto P. Rajkumar et al.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (2017)
Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations
Anjali N. Patel et al.
AMERICAN JOURNAL OF PSYCHIATRY (2017)
Impact of Antipsychotic Review and Nonpharmacological Intervention on Antipsychotic Use, Neuropsychiatric Symptoms, and Mortality in People With Dementia Living in Nursing Homes: A Factorial Cluster-Randomized Controlled Trial by the Well-Being and Health for People With Dementia (WHELD) Program
Clive Ballard et al.
AMERICAN JOURNAL OF PSYCHIATRY (2016)
The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study
Janet Sultana et al.
CNS DRUGS (2016)
Evaluating the effectiveness and cost-effectiveness of Dementia Care Mapping™ to enable person-centred care for people with dementia and their carers (DCM-EPIC) in care homes: study protocol for a randomised controlled trial
Claire A. Surr et al.
TRIALS (2016)
Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia A Randomized Clinical Trial
Jeffrey L. Cummings et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
On visual hallucinations and cortical networks: a trans-diagnostic review
Rowena Carter et al.
JOURNAL OF NEUROLOGY (2015)
A Double-Blind Randomized Placebo-Controlled Withdrawal Trial Comparing Memantine and Antipsychotics for the Long-Term Treatment of Function and Neuropsychiatric Symptoms in People With Alzheimer's Disease (MAIN-AD)
Clive Ballard et al.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (2015)
Predictors for Nursing Home Admission and Death among Community-Dwelling People 70 Years and Older Who Receive Domiciliary Care
Jon N. Wergeland et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA (2015)
Dronabinol for the Treatment of Agitation and Aggressive Behavior in Acutely Hospitalized Severely Demented Patients with Noncognitive Behavioral Symptoms
Matthew R. Woodward et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2014)
Psychosis in Alzheimer's Disease
Patrick S. Murray et al.
BIOLOGICAL PSYCHIATRY (2014)
Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
Anton P. Porsteinsson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
Jeffrey Cummings et al.
LANCET (2014)
Psychotic Alzheimer's disease is associated with gender-specific tau phosphorylation abnormalities
Jeremy Koppel et al.
NEUROBIOLOGY OF AGING (2014)
Tau phosphorylation is exaggerated in Alzheimer disease with psychosis
Patrick S. Murray et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2013)
Study of the use of antidepressants for depression in dementia: the HTA-SADD trial - a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine
S. Banerjee et al.
HEALTH TECHNOLOGY ASSESSMENT (2013)
Efficacy of Memantine for Agitation in Alzheimer's Dementia: A Randomised Double-Blind Placebo Controlled Trial
Chris Fox et al.
PLOS ONE (2012)
Chronic Divalproex Sodium to Attenuate Agitation and Clinical Progression of Alzheimer Disease
Pierre N. Tariot et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality
Clive Ballard et al.
EXPERT OPINION ON DRUG SAFETY (2011)
Randomized, Controlled Crossover Trial of Dronabinol, 2.5 mg, for Agitation in 2 Patients With Dementia
Sebastian Walther et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2011)
The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: A 12-week open-label pilot study
Sibel Cakir
Neuropsychiatric Disease and Treatment (2011)
Trajectories of cognitive decline in Alzheimer's disease
Patricia A. Wilkosz et al.
INTERNATIONAL PSYCHOGERIATRICS (2010)
Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions
Clive Ballard et al.
CURRENT OPINION IN PSYCHIATRY (2009)
Effect of Oxcarbazepine in the Treatment of Agitation and Aggression in Severe Dementia
Oskar H. Sommer et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2009)
Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimers disease
Peita D. Bruen et al.
BRAIN (2008)
Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis
S. Gauthier et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2008)
Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: A pooled analysis of 3 studies
Gordon K. Wilcock et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation
Michael J. Passmore
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2008)
Donepezil for the treatment of agitation in Alzheimer's disease
Robert J. Howard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Actigraphy in agitated patients with dementia - Monitoring treatment outcomes
R. Mahlberg et al.
ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE (2007)
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia
S Walther et al.
PSYCHOPHARMACOLOGY (2006)
Effect of enhanced psychosocial care on antipsychotic use in nurshig home residents with severe dementia: cluster randomised trial
J Fossey et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials
LS Schneider et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2006)
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease
C Ballard et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2006)
Neuroleptic drugs in dementia: benefits and harm
Clive Ballard et al.
NATURE REVIEWS NEUROSCIENCE (2006)
Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease
M. Garcia-Alloza et al.
NEUROPSYCHOLOGIA (2005)
Differential involvement of 5-HT1B/1D and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease
M Garcia-Alloza et al.
NEUROPSYCHOPHARMACOLOGY (2004)
A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil
SI Finkel et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2004)
Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease - A meta-analysis
NH Trinh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease
S Gauthier et al.
INTERNATIONAL PSYCHOGERIATRICS (2002)
Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment - Results from the Cardiovascular Health Study
CG Lyketsos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients
BG Pollock et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease
S Tekin et al.
ANNALS OF NEUROLOGY (2001)
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study
I McKeith et al.
LANCET (2000)
Psychotic symptoms in Alzheimer's disease are not associated with more severe neuropathologic features
RA Sweet et al.
INTERNATIONAL PSYCHOGERIATRICS (2000)
Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis
NB Farber et al.
ARCHIVES OF GENERAL PSYCHIATRY (2000)
Treatment of agitation in AD - A randomized, placebo-controlled clinical trial
L Teri et al.
NEUROLOGY (2000)
Share Paper
